

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. – 11. (Cancelled)

12. (Currently amended) ~~The A~~ compound selected from the group consisting of monocalcium bis((2E)-3-[3-[7-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]acrylate) and, (2E)-3-[3-[7-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]acrylate tris(hydroxymethyl)methylamine salt, ~~(2E)-3-[3-[7-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]acrylate diethanolamine salt, monocalcium bis(3-[3-[6-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-7-methyl-2-oxo-2H-chromen-4-yl]phenyl]propionate) and monocalcium bis(4-[3-[7-chloro-3-(2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl)-6-methyl-2-oxo-2H-chromen-4-yl]phenyl]butanoate), or a hydrate thereof.~~

13. (Cancelled)

14. (Currently amended) A crystal of the compound according to claim 12.

15. (Withdrawn-Currently amended) A ~~medicament pharmaceutical composition~~ comprising the compound according to claim 12 ~~or a crystal thereof and a pharmaceutically acceptable carrier.~~

16. (Withdrawn-Currently amended) The ~~pharmaceutical composition medicament~~ according to claim 15, which is an oral preparation.

17. (Withdrawn-Currently amended) The pharmaceutical composition medicament according to claim 15, which is a lipid-rich plaque regressing agent or an ACAT inhibitor.

18. – 20. (Cancelled)

21. (Withdrawn-Currently amended) A method for preventing or treating coronary syndrome, myocardial infarction, unstable angina, coronary artery restenosis after PTCA or stent placement, peripheral artery occlusion, hyperlipemia, cerebral infarction, cerebral apoplexy, Alzheimer's disease, multiple risk syndrome or metabolic syndrome, or regressing, inhibiting progression of or stabilizing an arteriosclerotic or atherosclerotic lesion in a mammal, which comprises administering an effective amount of the\_a compound according to claim 1-12 to the mammal.

22. (Withdrawn-Currently amended) The\_A method for regressing, inhibiting progression of or stabilizing an arteriosclerotic or atherosclerotic lesion in a mammal according to claim 21, which comprises administering the\_a compound according to claim 1-12 in combination with a HMG-CoA reductase inhibitor.

23. – 25. (Cancelled)